FDA Cites Arizona Stem Cell Firm for Unapproved Products

Drug Industry Daily
A A
The FDA issued an untitled letter to Arizona-based R3 Stem Cell for marketing unapproved stem cell products with claims to treat serious illnesses such as Lyme disease, Parkinson’s, diabetes, stroke, kidney failure and ALS.

To View This Article:

Login

Subscribe To Drug Industry Daily